MX2020006192A - Un conjugado de un analogo de tubulisina con enlazadores ramificados. - Google Patents

Un conjugado de un analogo de tubulisina con enlazadores ramificados.

Info

Publication number
MX2020006192A
MX2020006192A MX2020006192A MX2020006192A MX2020006192A MX 2020006192 A MX2020006192 A MX 2020006192A MX 2020006192 A MX2020006192 A MX 2020006192A MX 2020006192 A MX2020006192 A MX 2020006192A MX 2020006192 A MX2020006192 A MX 2020006192A
Authority
MX
Mexico
Prior art keywords
conjugate
analog
tubulisin
branched
branched linkers
Prior art date
Application number
MX2020006192A
Other languages
English (en)
Inventor
Yuanyuan Huang
Qingliang Yang
Shun Gai
Hangbo Ye
Huihui Guo
Xiaomai Zhou
Hongsheng Xie
Qianqian Tong
Linyao Zhao
Junxiang Jia
Wenjun Li
Yifang Xu
Lu Bai
Robert Yongxin Zhao
Xiang Cai
Jun Zheng
Jun Lei
Mingjun Cao
Xiaotao Zhuo
Xiuzheng Zhang
Original Assignee
Hangzhou Dac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Dac Biotech Co Ltd filed Critical Hangzhou Dac Biotech Co Ltd
Publication of MX2020006192A publication Critical patent/MX2020006192A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención hace referencia a la conjugación de un compuesto análogo de tubulisina con una molécula de unión a células con enlazadores de cadena ramificada/lateral para tener mejor administración del compuesto conjugado y el tratamiento dirigido de células anómalas. También hace referencia a un método de enlace ramificado de conjugación de una molécula de análogo de tubulisina a un ligando de unión a células, así como a métodos para usar el conjugado en el tratamiento dirigido de cáncer, infecciones y enfermedades autoinmunitarias.
MX2020006192A 2017-12-31 2017-12-31 Un conjugado de un analogo de tubulisina con enlazadores ramificados. MX2020006192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/120454 WO2019127607A1 (en) 2017-12-31 2017-12-31 A conjugate of a tubulysin analog with branched linkers

Publications (1)

Publication Number Publication Date
MX2020006192A true MX2020006192A (es) 2020-08-20

Family

ID=67064953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006192A MX2020006192A (es) 2017-12-31 2017-12-31 Un conjugado de un analogo de tubulisina con enlazadores ramificados.

Country Status (17)

Country Link
US (4) US11998584B2 (es)
EP (1) EP3621652A4 (es)
JP (2) JP7262817B2 (es)
KR (2) KR102603344B1 (es)
CN (1) CN111093707A (es)
AU (2) AU2017445144A1 (es)
BR (1) BR112020010405A2 (es)
CA (1) CA3085634C (es)
CL (1) CL2020001600A1 (es)
EA (1) EA202091217A1 (es)
IL (2) IL317268A (es)
MX (1) MX2020006192A (es)
NZ (1) NZ795845A (es)
PH (1) PH12020550657A1 (es)
SG (1) SG11202004801WA (es)
WO (1) WO2019127607A1 (es)
ZA (1) ZA202003211B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
EP3210627B1 (en) 2012-07-12 2022-12-21 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
IL317268A (en) 2017-12-31 2025-01-01 Hangzhou Dac Biotech Co Ltd Conjugation of a tubulin analog with branched linkers
CN118027137A (zh) 2018-12-21 2024-05-14 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
PH12021551776A1 (en) * 2019-01-31 2022-05-23 Hangzhou Dac Biotech Co Ltd A conjugate of an amanita toxin with branched linkers
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
PH12021552944A1 (en) * 2019-06-24 2022-07-25 Hangzhou Dac Biotech Co Ltd A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
KR20220024914A (ko) * 2019-06-24 2022-03-03 항저우 디에이씨 바이오테크 씨오, 엘티디 분지형 링커를 사용한 세포독성제 대 세포 결합 분자의 접합체
JP2022540395A (ja) * 2019-06-29 2022-09-15 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 細胞結合性分子－チューブリシン誘導体共役体及びその調製方法
EP3797796A4 (en) * 2019-08-07 2021-10-27 MabPlex International Co., Ltd. ANTIBODY INGREDIENT CONJUGATES AND USES THEREOF
MX2022007353A (es) 2019-12-17 2022-09-19 Univ Texas Anticuerpos novedosos ddr1 y sus usos.
EP3862023A1 (en) * 2020-02-05 2021-08-11 Hangzhou DAC Biotech Co, Ltd Conjugates of cell-binding molecules with cytotoxic agents
US11045546B1 (en) 2020-03-30 2021-06-29 Cytodyn Inc. Methods of treating coronavirus infection
CN115515937A (zh) * 2020-05-08 2022-12-23 范因斯坦医学研究院 用于合成肽模拟物的二聚体
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN112138170B (zh) * 2020-09-28 2022-05-20 广东药科大学 一种预防顺铂药源性聋的缀合物及其制备方法和应用
CN112755173B (zh) * 2020-12-31 2022-01-07 深圳市科达顺生物技术有限公司 用于治疗三阴性乳腺癌的Ii-Key/HER2杂交多肽药物及其制备方法
CN112961060B (zh) * 2021-02-09 2022-03-25 武汉大学 同位素标记的n,n-二甲基乙二胺及其制备方法和短链脂肪酸的分析方法
AU2022259314A1 (en) 2021-04-14 2023-11-30 Genequantum Healthcare (Suzhou) Co., Ltd. Linkers, conjugates and applications thereof
EP4355366A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and napoli
CN118475346A (zh) * 2021-09-08 2024-08-09 同宜医药（苏州）有限公司 药物制剂及其制备方法和用途
CN117980327A (zh) * 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4514336A1 (en) * 2022-04-28 2025-03-05 Scirosbio (FZC) Compositions and methods for treatment of cancer
US20250312289A1 (en) * 2022-06-17 2025-10-09 The Regents Of The University Of California Methods and compositions comprising tobacco mild green mosaic virus (tmgmv)
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
KR20260014538A (ko) * 2023-05-24 2026-01-30 항저우 시허 바이오테크놀로지 컴퍼니 리미티드 항체-약물 접합체에 의한 전립선암 및 다른 종양의 표적 치료
WO2025021118A1 (zh) * 2023-07-25 2025-01-30 海南先声再明医药股份有限公司 配体-药物偶联物及其偶联连接子
WO2025137247A1 (en) * 2023-12-22 2025-06-26 Milgraum Sandy S Topical compositions of glp-1 agonists and use of glp-1 agonists and compositions thereof in treating vitiligo

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005326A2 (de) * 2002-07-09 2004-01-15 Morphochem Aktiengellschaft Fu Tubulysinkonjugate
NZ580132A (en) 2007-03-14 2012-11-30 Endocyte Inc Binding ligand linked drug delivery conjugates of tubulysins to vitamins
EP3210627B1 (en) * 2012-07-12 2022-12-21 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
AU2012395148B2 (en) * 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
GB201402009D0 (en) * 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
UY36075A (es) * 2014-04-11 2015-10-30 Medimmune Llc Derivados de tubulisina
US20170290878A1 (en) 2014-09-25 2017-10-12 Endocyte, Inc. Methods of treating cancer with tubulysin conjugates
CN110279872A (zh) * 2014-11-11 2019-09-27 杭州多禧生物科技有限公司 细胞毒素分子同细胞结合受体分子的共轭体
CA2989269C (en) * 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
JP6817288B2 (ja) * 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
TWI852735B (zh) * 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
EP3411074A4 (en) * 2016-02-04 2019-09-04 Suzhou M-conj Biotech Co., Ltd. SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHOD FOR THE PRODUCTION AND USE THEREOF OF SUCH CONJUGATES
MX2018012803A (es) 2016-04-20 2019-06-24 Hangzhou Dac Biotech Co Ltd Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular.
AU2016429272A1 (en) * 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
KR20210125094A (ko) 2017-04-06 2021-10-15 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
IL317268A (en) 2017-12-31 2025-01-01 Hangzhou Dac Biotech Co Ltd Conjugation of a tubulin analog with branched linkers

Also Published As

Publication number Publication date
NZ764814A (en) 2024-02-23
KR102603344B1 (ko) 2023-11-16
KR20200097295A (ko) 2020-08-18
JP7637431B2 (ja) 2025-02-28
US20230165931A1 (en) 2023-06-01
AU2022205269A1 (en) 2022-08-11
EP3621652A4 (en) 2021-01-13
KR20230075530A (ko) 2023-05-31
US20230165930A1 (en) 2023-06-01
IL275274B2 (en) 2025-05-01
IL317268A (en) 2025-01-01
IL275274B1 (en) 2025-01-01
AU2017445144A1 (en) 2020-06-18
AU2022205269B2 (en) 2024-07-11
CL2020001600A1 (es) 2021-03-19
CA3085634A1 (en) 2019-07-04
ZA202003211B (en) 2024-04-24
US20230149502A1 (en) 2023-05-18
PH12020550657A1 (en) 2021-04-19
JP2023093531A (ja) 2023-07-04
US20200276261A1 (en) 2020-09-03
CA3085634C (en) 2023-11-14
EP3621652A1 (en) 2020-03-18
JP2021507928A (ja) 2021-02-25
BR112020010405A2 (pt) 2020-11-24
NZ795845A (en) 2026-01-30
US11998584B2 (en) 2024-06-04
CN111093707A (zh) 2020-05-01
WO2019127607A1 (en) 2019-07-04
KR102641565B1 (ko) 2024-02-27
JP7262817B2 (ja) 2023-04-24
SG11202004801WA (en) 2020-06-29
EA202091217A1 (ru) 2020-09-18
IL275274A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
ZA202003211B (en) A conjugate of a tubulysin analog with branched linkers
MX2025002072A (es) Un conjugado de un agente citotoxico y una molecula de union a celulas con enlazadores ramificados
ZA201907233B (en) Conjugation of a cytotoxic drug with bis-linkage
MX2023013592A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
NZ779060A (en) A conjugate of an amanita toxin with branched linkers
MX2018006218A (es) Conjugados de compuestos de tubulisina cuaternizada.
MX2022003930A (es) Conjugados de péptido de camptotecina.
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
MX2020010458A (es) Conjugados de camptotecina-peptido.
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
NZ708727A (en) Conjugate compounds
NZ737757A (en) Peptide oligonucleotide conjugates
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
ZA202203201B (en) Therapeutic conjugates
NZ737471A (en) Hydrophilic linkers for conjugation
WO2011103567A3 (en) Peptides and methods for inducing cell death
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
EA201591758A8 (ru) Подкожное введение adamts13
CY1123818T1 (el) Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο
ZA202101990B (en) Sulfomaleimide-based linkers and corresponding conjugates
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
EA202092369A1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака
PH12016502042A1 (en) Drug delivery conjugates for treating resistant cancer and for use in combination therapy